Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 162 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Kids Facing Difficult Medical Diagnoses Take Train To The ‘North Pole’... December 12, 2021 FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia November 3, 2021 Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer: Results... March 27, 2023 SIOG 2020: New Research in Caring for and Treating People With... November 12, 2020 Load more HOT NEWS 2022 ASCO Annual Meeting Research Round Up: New Research in Head... Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO... A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in cHL New independent tobacco review sets roadmap for a smokefree England for...
